Transcript Figure 14-10 - University of Belgrade

Tumor immunology
Content
IMMUNOLOGICAL SURVEILLANCE
TUMOR ANTIGENS
EFFECTOR MECHANISMS IN ANTITUMOR IMMUNITY
MECHANISMS OF EVASION OF THE
IMMUNE SYSTEM BY TUMORS
TUMOR IMMUNOTHERAPY
Immunosurveillance
Physiological function of the immune
system to recognize and destroy
malignantly transformed cells before
they grow into tumors, or to kill tumors
after they are formed
Tumor antigens
• Tumor-specific antigens (TSA)
Antigens expressed on tumor cells but not on normal
cells
• Tumor-associated antigens (TAA)
Antigens expressed concurently on normal cells
Figure 14-12
Figure 14-12
Figure 14-13
Effector mechanisms in
anti-tumor immunity
T lymphocytes
NK cells
Antibodies
Macrophages
Effector mechanisms in
anti-tumor immunity
T lymphocytes
NK cells
Antibodies
Macrophages
Figure 1-6
Figure 9-34 part 1 of 2
Figure 9-34 part 2 of 2
Effector mechanisms in
anti-tumor immunity
T lymphocytes
NK cells
Antibodies
Macrophages
Effector mechanisms in
anti-tumor immunity
T lymphocytes
NK cells
Antibodies
Macrophages
Mechanisms of evasion of
the immune response by
tumors
IMPORTANT ISSUES IN DESIGNING
EFFECTIVE CANCER VACCINE
Too less good things for initiation of antitumor
immune response
Failure to produce and/or present antigen
Failure to activate T cells
Too many bad things for maintenance of an effective
antitumor immune response
Immunosuppresive cytokines
Induction of immunoprivileges
Induction of regulatory cells
Figure 14-14 part 1 of 2
Figure 14-14 part 2 of 2
Tumor immunotherapy
Nonspecific
Specific
Passive
Monoclonal Abs
adoptive (LAK, TIL)
Active
Vaccination
Figure 14-17
IMPORTANT ISSUES IN
DESIGNING EFFECTIVE CANCER
VACCINE
To identify potent tumor rejection antigens
To stimulate an effective antitumor immune
response
To avoid autoimmune pathology